Company: AGIO
Filing Date: 2025-05-01
Form Type: 10-Q
Source: 0001439222-25-000036
Chunk: 102

Company: AGIOS PHARMACEUTICALS, INC.
Filing Date: 2025-05-01
Form: 10-Q
Item: Part I, Item 1
Chunk 102
---
.5 million for the three months ended March 31, 2025 compared to the three months ended March 31, 2024 was due to increased volume associated with PYRUKYND®.

Total Operating ExpensesThree Months Ended March 31,(In thousands)20252024Operating expenses:Cost of sales$1,085 $627 Research and development72,743 68,620 Selling, general and administrative41,527 31,014 Total operating expenses$115,355 $100,261 

Total Operating Expenses -  Three Months Ended March 31, 2025 vs. Three Months Ended March 31, 2024 – The increase in total operating expenses of $15.1 million for the three months ended March 31, 2025 compared to the three months ended March 31, 2024 was primarily due to an increase in selling, general and administrative expenses of $10.5 million, driven by an increase in commercial-related activities as we prepare for the potential approval of PYRUKYND® in thalassemia, and an increase in research and development expenses of $4.1 million which is described below under Research and Development Expenses.

Research and Development Expenses

Our research and development expenses, by major program, are outlined in the table below:Three Months Ended March 31,(In thousands)20252024PK activator (PYRUKYND®)$21,321 $26,036 Novel PK activator (tebapivat)5,388 1,895 Other research and platform programs3,444 3,685 Total direct research and development expenses30,153 31,616 Compensation and related expenses32,990 27,634 Facilities and IT related expenses & other9,600 9,370 Total indirect research and development expenses42,590 37,004 Total research and development expense$72,743 $68,620 

23

Total Research and Development Expenses - Three Months Ended March 31, 2025 vs. Three Months Ended March 31, 2024 – The increase in total research and development expenses of $4.1 million for the three months ended March 31, 2025 compared to the three months ended March 31, 2024 was primarily due to a $5.6 million increase in our indirect expenses, partially offset by a $1.5 million decrease in our direct expenses